Stable coronary artery disease after Coronary arteries Blood transport reconstruction
Conditions
Interventions
Experimental group:Yufeng Ningxin Drip Pill+routine treatment
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years male and female; 2. Diagnosis of stable coronary artery disease percutaneous coronary intervention coronary artery bypass grafting; 3. Volunteer and already signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. According to clinical manifestations and laboratory examinations, acute myocardial infarction was diagnosed within 1 month after the onset of acute myocardial infarction; 2. Combined with clinical manifestations and related examinations, discomfort symptoms were considered to be related to digestive system diseases, neck and shoulder diseases and back diseases; 3. Coronary angiography or coronary CTA after revascularization indicated that there were more than 75% stenosis in vessels over 2.0 mm; 4. Clinical manifestations and coronary imaging suggest that there is no coronary reflux, side branch involvement, stent thrombosis, coronary dissection and other PCI-related perioperative coronary ischemia; 5. Patients with severe cardiac insufficiency, NYHAIII-IV grade, left ventricular ejection fraction (LVEF) 55 mm, female > 50 mm); 6. Patients with severe valvular disease or valvular disease, non-ischemic dilated cardiomyopathy or hypertrophic cardiomyopathy that may require surgical or interventional treatment; 7. Patients with known severe liver dysfunction (ALT or AST levels more than three times higher than the upper limit of normal values), renal insufficiency (GFR < 30 ml/min), severe chronic obstructive pulmonary disease and pulmonary hypertension; 8. Patients with malignant tumors, lymphoma and neuropsychiatric disorders; 9. Within 3 months, there was a history of major surgery or trauma, active hemorrhage or cerebrovascular accident within 6 months; 10. Women who are known or ready for pregnancy or lactation; 11. During the first month of this study, I participated in other clinical studies or other clinical researchers; 12. According to the judgement of the researchers, patients who could not complete the study or could not comply with the requirements of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| peak VO2 %Pred; | — |
Secondary
| Measure | Time frame |
|---|---|
| oxygen pulse (VO2/HR);AT;?VO2/?W;Anginal frequency in four weeks;Visual analogue scale (VAS);Seattle angina scale (SAQ);Platelet function(by Thrombus test method); | — |
Countries
China
Contacts
Public ContactHongkai Li
Beijing Tongrentang co., LTD Science Institute
Outcome results
None listed